GoPath Diagnostics

01/22/2026

Prostate cancer tumor burden may be higher than it looks on your reports.

A new GoPath study, presented in part at the 101st Annual Meeting of the Western Section of the AUA, shows that using slide core length instead of gross core length can shift percent tumor involvement from 54.79% to 75.52% in the same biopsy cores. The blog details how this discrepancy affects common thresholds such as the 50% involvement cut‑off in Gleason 3+3 and 3+4 disease, with direct impact on active surveillance decisions. The study outlines practical steps for clinicians and pathologists to standardize slide‑based measurements and improve confidence in risk stratification.

Read more: https://www.gopathdx.com/blog/tpost/yvjt72xy41-the-difference-of-percent-tumor-involvem

01/14/2026

A new study shows that expanding genetic testing beyond family history can identify more women at risk for breast cancer. Researchers found that criteria-independent testing detected pathogenic variants in women who had no personal or family history of the disease. This approach may help clinicians catch risk factors earlier and improve prevention efforts.

Read more:

Criteria-independent genetic testing identifies more women with pathogenic breast cancer variants than guideline-based approaches.

01/09/2026

We’re often asked how genetic testing can impact a prostate cancer journey and which patients benefit most. ProstateNow™ provides clarity by analyzing inherited risk factors that inform prognosis and potential targeted therapy options.

To learn more about the genes we evaluate and how these results can personalize your treatment plan, visit: https://geneticsnow.com/prostatenow

01/07/2026

Colorectal cancer is increasingly being diagnosed during pregnancy and the postpartum period, often at later stages with worse outcomes. New research highlights how immune and inflammatory changes in pregnancy may mask symptoms, fuel tumor growth, and complicate treatment decisions, while emerging screening tools like ctDNA methylation assays could improve early detection for high-risk patients.

Read more:

Colorectal cancer diagnosed during pregnancy is an increasing concern as the incidence of colorectal cancer continues to rise among young adults. Immunological adaptations of pregnancy may promote more aggressive tumor characteristics, helping to explain the less favorable outcomes associated with c...

01/01/2026

🎊 Happy New Year from GoPath! 🎊

As we step into 2026, we're excited about the opportunities ahead and the continued partnerships that drive meaningful progress in patient care. Here's to new goals, shared successes, and another year of working together to advance diagnostic excellence. Wishing you health, happiness, and a strong start to the new year!

12/23/2025

🎁 Happy Holidays from GoPath Diagnostics! 🎁

As we wrap up the year, our team is grateful for the trust you place in us and the meaningful work we share in support of patient care. Thank you to our clients, partners, and colleagues who make progress possible every day. Wishing you a season filled with peace, good health, and time to recharge with those closest to you.

12/22/2025

🎄 We had a tree-mendous time celebrating the season together! 🎁

Thank you to our amazing team for making this year special. Cheers to good company, great memories, and a well-deserved break! 🥳✨

11/27/2025

Happy Thanksgiving from all of us at GoPath Diagnostics!

We’re grateful for the trust and collaboration of our partners, clinicians, and patients who make our work meaningful every day. Wishing you and your loved ones a wonderful holiday filled with gratitude and good health.

11/24/2025

MODY is often overlooked, yet it’s one of the most important monogenic diabetes conditions clinicians encounter. Identifying the underlying gene mutation can directly influence treatment, prognosis, and family risk assessment. Early recognition = better outcomes.

11/18/2025

Diabetes is a complex condition affecting millions across all ages and backgrounds, including rare forms like MODY that require specialized diagnosis and care. Early detection and awareness are vital, as many remain undiagnosed or face challenges managing their health. Understanding diabetes means recognizing its impact—from children to seniors and diverse communities—and the importance of education, support, and personalized treatment.

11/13/2025

We’re live at AMP 2025 in Boston! Stop by booth 1110 to learn more about our OncoTarget Series and how our comprehensive genomic profiling supports precision oncology. We are excited to connect with so many experts driving advancements in molecular diagnostics!

11/11/2025

Meet Mya—a college sophomore who was diagnosed with a rare form of diabetes (HNF1A MODY) at just age ten, and has since turned challenges into strength. As a middle schooler, Mya often felt left out, but early diagnosis gave her the knowledge and skills to advocate for herself and educate others about MODY. Today, she actively raises awareness, participates in research, and encourages other young people not to let diabetes define them. Discover how Mya is shaping her future—and inspiring her community—by sharing her journey and empowering others to do the same.

https://www.uchicagomedicine.org/forefront/pediatrics-articles/hnf1a-mody-diabetes-patient-story

Mya Abuzir is now a college student living with HNF1A MODY, a rare form of diabetes caused by a mutation in a single gene.